Stories

In the news

Press releases

Stories

Prime Insights

Media resources

Section divider

Stories 2020

June 23, 2020

Prime recognized as Star Tribune Top 150 Workplace

Annual ranking showcases employers of choice in Minnesota.


June 23, 2020

Prime Therapeutics uses Specialty Monitor™ to help Horizon Healthcare Services, Inc. identify more than $3.1M in drug cost savings

Industry-leading analytics solution, powered by the Artemetrx platform, informs near-term interventions designed to improve health outcomes and lower total cost of care.


June 19, 2020

Prime Named to 2020 Best Places to Work in New Mexico 

Albuquerque honored as an employer of choice for excellent morale, engagement and retention.


June 15, 2020

July 2020 decisions expected from the FDA

This synopsis looks ahead to the new drugs expecting an FDA decision in the month of July.  


June 8, 2020

Two Prime Medicare clients win PQA quality award

Alignment Health Plan (AHP) and Florida Blue both recognized for excellence in quality by Pharmacy Quality Alliance. This is the third year in a row that AHP has been recognized; the second year for Florida Blue. 


May 29, 2020

Real-world experience: Managing potential cures such as gene therapy

AMCP eLearning webinar showcases Prime’s collaboration with Blue Cross and Blue Shield of Kansas.


May 15, 2020

Prime Therapeutics is a local sponsor of the 2020 Twin Cities VIRTUAL Heart Walk

Employees raise funds to fight heart disease and prevent stroke.


May 13, 2020

Five Questions with Rachel Nelson

Delivering value and making Medicare easier to use. A conversation with Rachel Nelson, Vice President and General Manager of Federal Programs for Prime Therapeutics


April 24, 2020

For Medicare clients, quality drives outcomes and outcomes drive savings

Improved Star ratings for Medicare clients is a measure of Prime’s quality care and service to members. 


April 21, 2020

Driving Medicaid dollars to do more

Dedicated Medicaid teams drive value programming for Prime clients.


April 20, 2020

With hemophilia, many factors come into play

Keeping a close eye on the drug pipeline helped save millions in annual costs and reduced bleeding episodes for a 14-year-old boy with hemophilia.


April 16, 2020

May 2020 decisions expected from the FDA

This synopsis looks ahead to the new drugs expecting an FDA decision in the month of May.  


April 7, 2020

Prime’s Specialty Monitor® Solution Identifies $5 Million in Projected Savings for Blue Cross and Blue Shield of North Carolina

Actionable insights delivered better and faster than traditional methods.


April 7, 2020

How does Prime meet increased call volumes related to COVID-19?

It has hundreds of one-person contact centers across the country (most agents work safely from home and still meet the needs of members with empathy and technology). 


March 19, 2020

Prime Highlights Innovative Strategies for Payers and Patients at PBMI National Conference

Prime showcases how leveraging data, technology and intelligence contains costs and improves the patient experience.


March 18, 2020

Risdiplam approaching mid-2020 PDUFA date 

This will be the third, high cost drug treatment option emerging for spinal muscular atrophy in less than five years; many more are in the pipeline. 


March 13, 2020

April 2020 decisions expected from the FDA

This synopsis looks ahead to the new drugs expecting an FDA decision in the month of April. 


February 14, 2020

March 2020 decisions expected from the FDA

This synopsis looks ahead to the new drugs expecting an FDA decision in the month of March. March 2020 decisions.


February 19, 2020

PrimeCares: Improving the health of our communities through good works

Prime’s employee volunteers and financial contributions make a difference.  


January 15, 2020

February 2020 decisions expected from the FDA

A synopsis of the new drugs expecting an FDA decision in the month of February.


January 20, 2020

Breakthrough therapy for cystic fibrosis

Trikafka’s triple combination therapy may cover 90% of patients with cystic fibrosis.


January 22, 2020

FDA issues its first approval for an oral CGRP formulation for acute migraine 

Ubrelvy™ brings a new treatment option (oral) to a new drug class (CGRP) for patients with migraine.  Prime stays on top of the drug pipeline so our clients don’t fall behind.